Tagged with HAI

AstraZeneca Thailand Dr. Seeto, this is your first head of country position for AZ! Looking back at your first year-and-a-month, what have been the highlights and the key lessons learnt? Firstly, leading the Thai country organization has been a real privilege and honor. Looking back, I am proud of how the country…

The Government Pharmaceutical Organization (G Dr. Witit, when we interviewed your predecessor in 2006, we talked about the vital role and leading position GPO plays in the Thai pharmaceutical industry and the company’s investments in manufacturing facilities to improve access and affordability of drugs. What have been some of the most important milestones since you…

Zuellig Pharma Thailand ‘When markets are inefficient, relationships are important. When markets are more efficient, relationships become less important because the markets become more systematic, professional, and objective in the way they operate,’ said Mr. Zwisler, former CEO of Zuellig Pharma Asia Pacific when we interviewed him in China. At which development stage…

Novo Nordisk Thailand Novo Nordisk is one of the very few pharmaceutical multinationals that have a strong focus on one therapeutic area. Although the company has a presence in other disease areas, diabetes remains its leading cause. Could you give us a brief overview of the evolution of diabetes in Thailand compared to…

Genzyme (Shanghai) In 2006, Genzyme’s global CEO, Henri Termeer, said he is “personally very interested in China” and that he expects the company to build a capable infrastructure in ten years. We’re now 30% closer to the deadline. How has this deep commitment to China resulted in developments in the country and…

Medicilon/MPI Preclinical Research Shanghai You completed your higher education in the US and worked there for a period afterwards; what caused you to move back to China and start this company? A lot of people are now returning to China after gaining extensive experience in the US. I personally enjoyed the vast experience that…

Roche Thailand Dr Ammelburg, you have been working for Roche for more than 25 years now, time essentially spent between your home country Germany and Thailand. After more than 10 years spent here, what would you consider to be the main specificities of the Thai Pharma industry? The Thai market is not…

Invida Thailand You are General Manager for Thailand and Vietnam; two markets that certainly interest companies but at a very different stage of development. What are according to you the main differences between the Thai and the Vietnam market? Government regulation in Vietnam is higher throughout the value chain, whereas Thailand tends…

Bayer Thailand Mr. Ammelburg of Roche described Thailand as a very difficult and different market and according to PReMA figures there was only 2 percent growth last year. Nevertheless, global projections rank Thailand as 12th among emerging countries in pharma and anticipate Thailand becoming the eighth largest economy and market by 2016.…

Thai Pharmaceutical Manufacturers Association TPMA is the main association bringing together the local manufacturers in Thailand. What do you consider to have been the main milestones and achievements since your inception? We haven’t reached any milestones yet. Our first milestone will be to open and free the pharmaceutical market in Thailand by breaking the…

PREMA Thailand PReMa was established in 2004 after a period of transformation to represent the growing role of its members, research-based companies. To begin with, could you explain us the main milestones and achievements of the organization? PReMA has been present in Thailand for 42 years. The association only changed and took…

Thailand Thailand might already have become a medical tourism destination but the country still needs to sort out serious issues on its local market as the country healthcare system is largely underfunded, the country depends on imported drugs and APIs, local companies are lagging behind in terms of manufacturing practices and…